新康华生物揭牌仪式在成都举行

Core Viewpoint - The acquisition of Kanghua Biotech by the Shanghai Biopharmaceutical M&A Fund through Wankexin Biotech marks a significant development in the biopharmaceutical industry, aiming to enhance Kanghua's capabilities and market position in the vaccine sector [1]. Group 1: Acquisition Details - The acquisition was officially completed on November 27, 2025, during the unveiling and ecological cooperation conference held in Chengdu [1]. - The event was attended by various leaders and representatives from the biopharmaceutical industry, indicating strong support and interest in the collaboration [3]. Group 2: Strategic Vision and Goals - Kanghua Biotech's Vice Chairman emphasized the need for fresh blood to drive development, highlighting the importance of the partnership with the M&A fund for future progress [3]. - The President of Shanghai Shiyuan Group expressed hopes that the acquisition would facilitate collaboration between Shanghai and Chengdu in research, clinical trials, and industrialization [7]. Group 3: Industry Context and Opportunities - The President of the China Vaccine Industry Association noted that the vaccine industry in China is facing development opportunities, with an improving policy environment that could benefit Kanghua Biotech [5]. - Kanghua Biotech aims to leverage its existing rabies vaccine foundation to build a comprehensive rabies prevention service system [5]. Group 4: Strategic Partnerships - During the conference, Kanghua Biotech signed strategic agreements with several partners, including Shanghai Pharmaceutical Holdings and eight service providers, to support market expansion and channel development [12][14].